EPHA2 and osteosarcoma: Indeed, we showed that EphA2 targeting with the small molecule inhibitor ALW-II-41-27 resulted in marked reduction in cell growth and cell viability in four in vitro models, which we derived from primary osteosarcoma, Ewing’s sarcoma and chondrosarcoma tumor tissues.